

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(use several sheets if necessary)

SERIAL NO. 10/827,007	ATTORNEY DOCKET NO. 3352.2.1.3		
FILING DATE April 19, 2004	GROUP ART UNIT 1653		
APPLICANT(S): Yao Xior	no Hu et al.		

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER DATE		NAME	CLASS/ SUBCLASS	FILING DATE	
A)	A1	6,183,746	Feb. 6, 2001	Urban et al.	424/186.1	10/9/98	
	A2	6,096,869	Aug. 1, 2000	Stanley et al.	530/351	3/22/96	
	A3	5,932,412	Aug. 3, 1999	Dillner et al.	435/5	9/22/97	
	A4	5,753,233	May 19, 1998	Bleul et al.	424/204.1	6/6/95	
	A5	5,629,161	May 13, 1997	Muller et al.	435/7.1	12/23/94	
	A6	5,629,146	May 13,1997	Dillner et al.	435/5	6/25/91	
J	A7	4,777,239	Oct. 11, 1988	Schoolnik et al.	530/326	7/10/86	

FOREIGN PATENT DOCUMENTS

EXAMINER		DOCUMENT			CLASS/	TRANSLATION	
INITIAL		NUMBER	DATE	COUNTRY	SUBCLASS	YES	NO
A	A8	WO 99/10744	March 4, 1999	Deutschland	GO1N 33/569		х
	A9	EP 0 594 613	Nov. 28, 1991	Sweden	G01N 33/569	х	
	A10	EP 0344940	Dec. 12, 1989	European	C07K 7/06	х	
V	A11	WO 87/01375	Mar. 12, 1987	France	C07K 15/00		Х

NON-PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT (Including Author, Title, Source, and Pertinent Pages
AJ	A12	Petter et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types -6,-11,-16,-18 and 31-virus-like particles in human-immunodeficiency-virus-seropositive-women, Journal of General Virology, 81:701-8, 2000
A)	A13	Dreau et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery, 231(5):664-71, 2000

EXAMINER	DATE CONSIDERED	4/6/05
----------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

	6	IPE	
	JUL	12	VC33 30
(E	T&	RADENARY	

RIDAVAR		
A	A14 '	Wright et al., HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association, 283:81-6, 2000
	A15	Zumbach et al., Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma, International Journal of Cancer, 85:815-8, 2000
	A16	Mellin et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.), 89:300-4, 2000
·	A17	Frisch et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer, 88(6):1464-9, 2000
	A18	Pirog et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology, 157:1055-62, 2000
	A19	Cuzick et al., A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions, British Journal of Cancer, 83(5):561-5, 2000
	A20	Hagensee et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology, 94:653-8, 1999
	A21	Silins et al, Serological evidence for protection by human papillomarvirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology, 80: 2931-6, 1999
	A22	Nobbenhuis et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet, 354:20-5; 1999
	A23	Sun et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiology Biomarkers & Prevention, 8(10):935-40, 1999
	A24	Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology, 189:12-19, 1999
	A25	Rice et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology, 9:15-21, 1999
	A26	Meschede et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology, 36(2):475-80, 1998
	A27	Arends et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology, 51:96-103, 1998
	A28	Lowy et al., Papillomaviruses: prophylactic vaccine prospects, Biochimistre et Biophysica Acta, 1423(1):M1-8, 1998
	A29	Clavel et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology, 51(1):38-43, 1998

	/		
EXAMINER		DATE CONSIDERED	416105

	<u> </u>		
TA TRIOP	7)	A30	Sugase et al., Distinct manifestations of human papillomaviruses in the vagina, International Journal of Cancer, 72: 412-5, 1997
		A31	Bryan et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology, 53:185-8, 1997
		A32	Verdon ME, Issues in the management of human papillomavirus genital disease, American Family Physician, 55:1813-16, 1997
		A33	Konya et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology, 78:2615-20, 1997
		A34	Anonymous, Cervical cancer, NIH Consensus Statement Apr 1-3; 14(1):1-38, 1996
		A35	Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, Thorax, 51:887-93, 1996
		A36	Birdsong C.G., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 13:283-8, 1996
		A37	Boryslewicz et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet, 347:1523-7, 1996
		A38	Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Disease, 713:314-20, 1996
		A39	Ferency et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology, 1775:651-6, 1996
		A40	Cox et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology, 172:946-64, 1995
		A41	Chee et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology, 57:226-231, 1995
		A42	Gregoire et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute, 87(22):1705-9, 1995
		A43	Muller et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology, 104:138-41, 1995
		A44	Fu et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology, 10:235-41, 1994
		A45	Fu et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology, 29:168-88, 1994
	/	A46	Hutchinson et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor, American Journal of Clinical Pathology, 101:215-33, 1994

EXAMINER	DATE CONSIDERED 4/6/05

<u> </u>			
A PARTY A	D	A47	Hamsikova et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Disease, 170:1424-31, 1994
		A48	Park et al., Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses, Journal of Virological Methods, 45:303-318, 307, 1993
		A49	Slawson et al., Follow up papanicolau smear for cervical atypia: Are we missing significant disease?, Journal of Family practice, 36(3):289-93, 1993
		A50	Jochmus et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Problems, 6:319-25, 1992
		A51	Lorincz et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology, 79:328-37, 1992
		A52	Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute, 84:394-8, 1992
		A53	Harlan et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health, 81:885-91, 1991
		A54	Kochel et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology, 182:644-54, 1991
		A55	Hu YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal, 2:8-10, 1990
	/	A56	Hayward et al., Who gets screened for cervical and breast cancer?, Archives of Internal medicine, 148:1117-81, 1988.

Z-MLL CLIENTS/3352 Impact Diagnostics/3352-2-1-3/3352-2-1-3 PAT-FIL-IDS PTD-1449 040708 wpd

EXAMINER	DATE CONSIDERED	4/6/05